Issues

Home > Issues (Page 9)

December 21, 2021 Industry Trends

Even health care answers to the law of supply and demand. Before the pandemic, demand for care was surging as our nation aged. Supply has not kept up. More than 83 million Americans live in areas where there’s a shortage of primary care health professionals, according to the federal government. Rising demand coupled with limited supply is a recipe for high prices. And now, with a new variant of covid-19 in our midst, demand for care will only increase. Relaxing the laws that limit what...

December 21, 2021 Price and Costs

Wayne Winegarden, PhD, Discusses the Value of an Interchangeable Designation for Adalimumab Biosimilars December 19, 2021 Skylar Jeremias The Center for Biosimilars® interviewed Wayne Winegarden, PhD, senior fellow in business and economics at Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation. Click here to watch. Winegarden talked about how interchangeability designations are more important for biosimilars referencing adalimumab (Humira) because they would not administered by a physician in a clinic, unlike oncology biosimilars, which pharmacists do not interact with...

December 21, 2021 Policy Proposals

A health insurance “public option” is a long-cherished goal for many Democrats. Yet, progress on that goal has stalled at the national level. But three states — Washington, Nevada, and Colorado— have gone ahead with such schemes. Another 16 are considering them. Washington’s public plan is about to complete its first year in business. Colorado officials, meanwhile, have to create their standardized health benefit plan by the end of this year. We can be sure that the White House and Democrats in...

December 20, 2021 Policy Proposals

Open enrollment on Obamacare’s health insurance exchanges is in full swing. Consumers in most states, including the 33 that use the federally operated HealthCare.gov, have until Jan. 15 to sign up for coverage for 2022. The Biden administration says things have never been better, and that premiums are declining, more insurers are participating in the markets, and enrollment is at an all-time high. Dig a little deeper, and Obamacare’s troubles become evident. Premiums are ticking down only after rising for years. Much of the coverage on offer...

December 20, 2021 Policy Proposals

Senate Democrats have delayed action on their multi-trillion-dollar Build Back Better Act until the New Year. If it passes, even more people will be dependent on the federal government for health coverage. It would represent the latest stepping-stone toward single-payer health care, which progressives like Senator Bernie Sanders, I-Vt., have dreamed of implementing for some time. New research from the Fraser Institute, a Canadian think tank, offers a glimpse of what can happen when the government completely dominates the healthcare market. This year, Canadians faced...

December 16, 2021 Coronavirus - Alternate

Dr. Henry Miller joins the John Batchelor Show to talk about the latest news coming out of the United Kingdom, NHS reports on omicron, how the new variant compares to other variants of the COVID-19 virus, and what it means for Europe and the United States. Miller also talks about how transmissible omicron is, how effective vaccines and boosters could be, and it's impact on lockdowns, mask mandates, and travel. ...

December 16, 2021 Industry Trends

Last week, President Joe Biden emphasized the importance of the drug pricing proposals in the Democrats' roughly $2 trillion Build Back Better spending package. "I think it's safe to say that all of us, all of us, whatever our age, wherever we live, we can agree that prescription drugs are outrageously expensive in this country," Biden said. "Under my Build Back Better bill, which has passed the House of Representatives, it won't be the same way." Build Back Better would make significant changes to drug pricing...

December 13, 2021 Coronavirus

Good public health policy is welcome, even when long delayed. So we should cheer the Biden administration's announcement earlier this month that Covid-19 rapid-result antigen tests (RATs), which tell you in as little as 15 minutes whether you're infected, will be covered by private insurance. For uninsured Americans, the government would make 50 million free tests available, to be distributed through health clinics and other sites in rural and underserved communities. Assuming that they can detect the new Omicron variant along with...

December 13, 2021 Price and Costs

Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs. They will also include increases in other types of healthcare spending as less drug access would, ironically, increase hospitalizations and use of other healthcare services and could more than offset any...

December 13, 2021 Policy Proposals

In the midst of the Covid-19 crisis, there's some good news on the health care front. Cancer mortality rates are declining in the United States, according to a recent report from the National Cancer Institute. Sadly, patients in other countries may not be so lucky. Though the United States has a higher incidence of cancer, other wealthy nations report worse outcomes in terms of recovery and survival. This points to the effectiveness of American health care and reveals the flaws in other...

December 13, 2021 Industry Trends

Earlier this month, President Joe Biden unveiled a plan to make at-home COVID-19 tests free for people with private insurance. They'll have to pay for the tests first, then submit receipts to their insurer to get reimbursed. Only the government could come up with a plan so unnecessarily complicated. The Biden administration defended the overly bureaucratic policy on the grounds of cost. But bureaucracy is one of the main reasons at-home tests have been so difficult to find in the first place. As...

December 9, 2021 Industry Trends

The Center for Biosimilars® interviewed Wayne Winegarden, PhD, senior fellow in business and economics at Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation. Winegarden said that because of the high costs associated with Humira (reference adalimumab) and Enbrel (reference etanercept), biosimilars of these agents are needed to establish a competitive marketplace and to drive down costs. He said the long exclusivity periods that the makers of Humira and Enbrel have secured must end to allow greater affordability;...

December 7, 2021 Coronavirus

Dr. Henry Miller and John Batchelor breakdown the latest developments of Omicron, a new variant of the coronavirus that was recently detected in South Africa. Miller talks about the latest information regarding infections, vaccine efficacy, and how countries are responding to the news. ...

December 6, 2021 Industry Trends

Several hospitals in New Mexico activated crisis standards of care last month in response to a surge in COVID-19 patients. Earlier this fall, Alaska and Idaho did the same. In some places, providers were forced to begin rationing treatment based on the likelihood of survival. It was a shocking spectacle for many Americans, accustomed as we are to hospitals with enough beds, equipment, and doctors to go around. It only took 22 months of an unprecedented pandemic for the healthcare system in...

December 3, 2021 Coronavirus-Alternate2

Is the United States on the cusp of a new wave of COVID-19 devastation, thanks to the omicron variant? The Biden administration has banned travel to the United States from eight countries in southern Africa. Public officials nationwide are calling for vigilance and caution — and for people to get vaccinated or boosted. Omicron certainly merits watching. But our leaders must not overreact by turning back to lockdowns, forced closures, and curbs on gatherings because they feel the need to do something. The consensus among many scientists...

November 29, 2021 Blog, Coronavirus, Price and Costs

This month, Delta Airlines began levying a $200 monthly surcharge on unvaccinated employees enrolled in the company’s health plan for the financial “risk” they are supposedly imposing on the company. The airliner is not alone. A major health-care system in Louisiana plans to do the same for unvaccinated spouses on its health plan next year. And a retailer in Utah announced last month that unvaccinated employees would have to pay extra for insurance. In other words, medical underwriting — the practice of...

November 29, 2021 Blog, Coronavirus, Innovation, Issues

Earlier this month, the Biden administration bought 10 million courses of Pfizer's new COVID-19 pill, Paxlovid. Thanks to the Food and Drug Administration, however, it may be months before anyone can take it, as the agency hasn't yet offered up a timetable for approving it. Its inaction will almost certainly result in scores of preventable deaths. In clinical trials, Paxlovid proved nearly 90% effective at preventing hospitalization and death. The results were so promising, Pfizer ended its trial of the drug early. It would have been...

November 23, 2021 Innovation

Millions of Americans may soon be able to hear a bit easier. The Food and Drug Administration just announced a new rule that would permit over-the-counter sales of hearing aids. Regulators are soliciting comments from the public. This move to liberalize the market for hearing aids is an unmitigated piece of good news. It recognizes that patients should have greater control over the care they receive, and it promises to increase competition in the market for hearing aids, saving consumers money...

November 23, 2021 Coronavirus

An overwhelming consensus on any topic is very rare these days. But many Americans, whatever their political leanings, seem to feel that the policies, communications, and actions of the public health "experts" and politicians about the COVID-19 pandemic have been confusing, sometimes contradictory, and in some cases, inconsistent with the scientific evidence. Whether it was flip-flops on the effectiveness of masks, seemingly inane restrictions on certain activities, or baseless advocacy of ineffective drugs, the past 20 months have provided numerous reasons...

November 23, 2021 Industry Trends

Earlier this month, President Biden tapped Dr. Robert Califf to lead the Food and Drug Administration. The agency had been operating without a Senate-approved commissioner for almost a year. In my last column, I detailed how the FDA's failures reviewing and approving tests for COVID-19 have prolonged the pandemic. This week, we have a new source of dysfunction to explore—the FDA's foot-dragging on antiviral pills that treat COVID-19 and booster shots. Americans are needlessly suffering—and dying—because of that dysfunction. Since President Biden took office, FDA veteran...